Sugi Predict

Sugi Predict / Compounds / SCHEMBL1807646

SCHEMBL1807646

SCHEMBL1807646

CC(=O)N1CCc2ccc(S(=O)(=O)Cl)cc21

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.64
▸ SMN1; SMN2 Q16637 1/20 0.64
▸ NOTUM Q6P988 6/20 0.64
▸ LMNA P02545 2/20 0.61
▸ KMT2A Q03164 2/20 0.61
▸ PKM P14618 1/20 0.61
▸ KDM4E B2RXH2 1/20 0.55
▸ HDAC3 O15379 1/20 0.53
▸ HDAC4 P56524 1/20 0.53
▸ HDAC1 Q13547 1/20 0.53
▸ HDAC7 Q8WUI4 1/20 0.53
▸ HDAC2 Q92769 1/20 0.53
▸ HDAC10 Q969S8 1/20 0.53
▸ HDAC11 Q96DB2 1/20 0.53
▸ HDAC8 Q9BY41 1/20 0.53
▸ HDAC6 Q9UBN7 1/20 0.53
▸ HDAC9 Q9UKV0 1/20 0.53
▸ HDAC5 Q9UQL6 1/20 0.53
▸ MAPK1 P28482 1/20 0.49
▸ TDP1 Q9NUW8 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1908587 0.92 TDP1 (0.58) ALDH1A1SMN1; SMN2NOTUMLMNAKMT2A
SCHEMBL1021359 0.88 NOTUM (0.64) ALDH1A1SMN1; SMN2NOTUMLMNAKMT2A
SCHEMBL29737158 0.88 NOTUM (0.64) ALDH1A1SMN1; SMN2NOTUMLMNAKMT2A
SCHEMBL1803594 0.88 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2NOTUMLMNAKMT2A
SCHEMBL14059166 0.85 ALDH1A1 (0.64) ALDH1A1SMN1; SMN2NOTUMLMNAKMT2A
SCHEMBL1820571 0.83 KMT2A (0.65) ALDH1A1SMN1; SMN2NOTUMLMNAKMT2A
SCHEMBL18391775 0.82 KMT2A (0.64) ALDH1A1SMN1; SMN2NOTUMLMNAKMT2A
SCHEMBL1908607 0.80 TP53 (0.70) ALDH1A1SMN1; SMN2LMNAKMT2APKM
SCHEMBL3128006 0.78 NOTUM (0.42) ALDH1A1SMN1; SMN2NOTUMLMNAKMT2A
SCHEMBL5793078 0.78 NOTUM (1.00) ALDH1A1SMN1; SMN2NOTUMLMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250223266-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2025-07-10 — — US disclosed
CN-120051465-A Novel heterobicyclic compounds for inhibiting YAP-TEAD interactions and pharmaceutical compositions containing the same 韩美药品株式会社 2025-05-27 — — CN disclosed
US-12129236-B2 PARG inhibitory compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-10-29 — — US disclosed
CN-112979631-B PARG inhibiting compounds 癌症研究科技有限公司 2024-09-20 — — CN disclosed
US-20210380539-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-12-09 — — US disclosed
EP-3907224-A1 PARG INHIBITORY COMPOUNDS Cancer Research Technology Limited (GB) 2021-11-10 — — EP disclosed
EP-3233845-B1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECH LTD (GB) 2021-07-21 — — EP disclosed
CN-112979631-A PARG inhibiting compounds 癌症研究科技有限公司 2021-06-18 — — CN disclosed
US-10995073-B2 PARG inhibitory compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-05-04 — — US disclosed
CN-107295799-B PARG inhibiting compounds 癌症研究科技有限公司 2021-03-16 — — CN disclosed
US-20040018192-A1 Integrin expression inhibitors EISAI CO., LTD. (JP) 2004-01-29 — — US disclosed
EP-1335720-A1 SULPHONAMIDES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES Bayer Aktiengesellschaft (DE) 2003-08-20 — — EP disclosed
US-20030144507-A1 Sulfonamide-containing heterocyclic compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2003-07-31 — — US disclosed
US-6498183-B1 TREATMENT AND PROPHYLAXIS OF DISORDERS CAUSED BY HERPES VIRUSES, IN PARTICULAR HUMAN CYTOMEGALOVIRUS BAYER AKTIENGESELLSCHAFT (DE) 2002-12-24 — — US disclosed
EP-1258252-A1 INTEGRIN EXPRESSION INHIBITORS Eisai Co., Ltd. (JP) 2002-11-20 — — EP disclosed
EP-1243583-A1 HETEROCYCLIC COMPOUNDS HAVING SULFONAMIDE GROUPS Eisai Co., Ltd. (JP) 2002-09-25 — — EP disclosed
WO-2002036115-A1 SULPHONAMIDES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES BAYER AKTIENGESELLSCHAFT (DE) 2002-05-10 — — WO disclosed
EP-1177171-A1 SUBSTITUTED INDOLE SULFONAMIDES AS ANTIVIRAL AGENTS Bayer Aktiengesellschaft (DE) 2002-02-06 — — EP disclosed
WO-2000076966-A2 INDOLINYLAMIDE DERIVATIVES AND THE USE THEREOF AS ANTIVIRAL DRUGS BAYER AKTIENGESELLSCHAFT (DE) 2000-12-21 — — WO disclosed
WO-2000066553-A1 SUBSTITUTED INDOLE SULFONAMIDES AS ANTIVIRAL AGENTS BAYER AKTIENGESELLSCHAFT (DE) 2000-11-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210380539-A1 PARG INHIBITORY COMPOUNDS PARP11, PARG, PARP16 ALDH1A1 1411/4885SMN1; SMN2 3672/4885NOTUM 2783/4885
US-10995073-B2 PARG inhibitory compounds PARG, PARP11, PARP16 ALDH1A1 1483/4885SMN1; SMN2 3372/4885NOTUM 2619/4885
US-12129236-B2 PARG inhibitory compounds PARP11, PARG, PARP16 ALDH1A1 1411/4885SMN1; SMN2 3672/4885NOTUM 2783/4885
US-20040018192-A1 Integrin expression inhibitors ITGB1, ITGB4, ITGB5 ALDH1A1 1266/4885SMN1; SMN2 2404/4885NOTUM 4259/4885
US-20250223266-A1 PARG INHIBITORY COMPOUNDS PARG, PARP11, PARP16 ALDH1A1 1483/4885SMN1; SMN2 3372/4885NOTUM 2619/4885
US-20030144507-A1 Sulfonamide-containing heterocyclic compounds SLC5A2, SLC5A1, CBR3 ALDH1A1 1018/4885SMN1; SMN2 1987/4885NOTUM 2361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.